CA2685214A1 - Forme posologique orale a liberation regulee amelioree - Google Patents

Forme posologique orale a liberation regulee amelioree Download PDF

Info

Publication number
CA2685214A1
CA2685214A1 CA002685214A CA2685214A CA2685214A1 CA 2685214 A1 CA2685214 A1 CA 2685214A1 CA 002685214 A CA002685214 A CA 002685214A CA 2685214 A CA2685214 A CA 2685214A CA 2685214 A1 CA2685214 A1 CA 2685214A1
Authority
CA
Canada
Prior art keywords
composition
bupropion
cellulose
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002685214A
Other languages
English (en)
Other versions
CA2685214C (fr
Inventor
Boyong Li
Chih-Ming Chen
Xiu Xiu Cheng
Avinash Nangia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2796884A priority Critical patent/CA2796884A1/fr
Publication of CA2685214A1 publication Critical patent/CA2685214A1/fr
Application granted granted Critical
Publication of CA2685214C publication Critical patent/CA2685214C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
CA2685214A 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree Expired - Fee Related CA2685214C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2796884A CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26745601P 2001-02-08 2001-02-08
US26745701P 2001-02-08 2001-02-08
US60/267,456 2001-02-08
US60/267,457 2001-02-08
CA2433915A CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2433915A Division CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2796884A Division CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Publications (2)

Publication Number Publication Date
CA2685214A1 true CA2685214A1 (fr) 2002-08-15
CA2685214C CA2685214C (fr) 2013-01-22

Family

ID=26952450

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2796884A Abandoned CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2685214A Expired - Fee Related CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2796884A Abandoned CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Country Status (3)

Country Link
EP (1) EP1357898A4 (fr)
CA (3) CA2796884A1 (fr)
WO (1) WO2002062299A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
WO2006123364A2 (fr) * 2005-03-14 2006-11-23 Sun Pharmaceutical Industries Limited Systeme d'administration de medicament par voie orale
KR20090088913A (ko) * 2006-11-21 2009-08-20 맥네일-피피씨, 인코포레이티드 개질된 방출형 진통 현탁제
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8956654B2 (en) 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141582C (fr) * 1992-08-05 2003-09-30 Angelo Mario Morella Composition pharmaceutique sous forme de pastilles
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
CA2796884A1 (fr) 2002-08-15
WO2002062299A3 (fr) 2003-04-24
CA2685214C (fr) 2013-01-22
EP1357898A4 (fr) 2005-07-13
EP1357898A2 (fr) 2003-11-05
CA2433915A1 (fr) 2002-08-15
WO2002062299A2 (fr) 2002-08-15
CA2433915C (fr) 2010-04-20

Similar Documents

Publication Publication Date Title
US7771750B2 (en) Controlled release oral dosage form
US6589553B2 (en) Controlled release oral dosage form
JP2637981B2 (ja) 吸収制御薬剤組成物
CA2686094A1 (fr) Methode de fabrication d'un element semiconducteur
AU2002330211B2 (en) Timed, sustained release multi-particulate dosage forms of propranolol
EP1879556B1 (fr) Systemes de liberation chronocontrolee par impulsions
CA2426883C (fr) Formulations a liberation modifiee par methylphenidate
AU757915B2 (en) Controlled release bupropion formulation
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
KR20080007252A (ko) 양성 전립선 과다형성증용 치료 조합물
HUE029680T2 (en) Dispensing systems containing weakly basic active ingredients and organic acids
US10213389B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US20030035840A1 (en) Controlled release oral dosage form
WO2007117110A2 (fr) Granules à libération prolongée contenant du chlorhydrate de tamsulosine et leurs procédés de préparation
CA2433915C (fr) Forme posologique orale a liberation regulee amelioree
EP1629834A1 (fr) Composition pharmaceutique de tolterodine avec liberation soutenue
US20090297602A1 (en) Modified Release Loxoprofen Compositions
AU2002253907A1 (en) Improved controlled release oral dosage form
JP2005510449A (ja) 改良型制御放出経口剤形
AU2013273835B2 (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200210